TrialCancer research and treatment2019

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.

Cheol-Kyu Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.